A new patent application pertaining to a Coronavirus vaccine candidate propelled a biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, March 10, 2020 (as of 4 pm EST):
Vaxil Bio Ltd. (TSXV:VXL), a biotech stock, climbed 22% to $0.14 on Tuesday after announcing that it has submitted a new patent application for its anti-infective vaccines platform as a result of its recently-announced Coronavirus (COVID19) candidate discovery.
As well, shares of Horizon North Logistics Inc. (TSX:HNL) surged 26% to $0.73 as the provider of industrial, commercial, and residential products and services said it has agreed to acquire Dexterra Integrated Facilities Management, a wholly-owned subsidiary of Fairfax Financial Holdings Limited, in an all-stock transaction that would see Fairfax owning 49% of Horizon North shares on a fully-diluted basis. Dexterra had more than $260 million in revenue with EBITDA of $16.5 million in 2019.
Correvio Pharma Corp. (TSX:CORV), meanwhile, reported that it has partnered with privately-held Hong Kong Teson Pharma Limited for the commercialization of Aggrastat, covering the territories of mainland China and Macau. Aggrastat is Correvio’s marketed asset for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Correvio Pharma stock moved up 17% to $0.61 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Vaxil Bio Ltd. (TSXV:VXL), a biotech stock, climbed 22% to $0.14 on Tuesday after announcing that it has submitted a new patent application for its anti-infective vaccines platform as a result of its recently-announced Coronavirus (COVID19) candidate discovery.
, on Tuesday.){kind=link}